Charles Russell Speechlys advises Kreos Capital on €20 million growth capital facility in Medtech company
Charles Russell Speechlys have advised Kreos Capital on its additional growth capital facility of €20 million in Cellnovo Limited (“Cellnovo”), the wholly-owned subsidiary company of Cellnovo Group SA, a Med Tech company marketing the first mobile, connected, all-in-one diabetes management system, listed on Euronext Paris. This is a follow on facility by Kreos subsequent to its €7 million growth capital facility in 2015 and its €5 million growth capital facility in 2017.
The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Legal Director), Amelly Kok (Associate) and Dafni Loizou (Associate) from our Corporate Team, and Paul Kay (Partner) from our Banking Team. Foreign counsel who have advised on this transaction are Reinhart Marville Torre (French law).
News & Insights
Setting up a charitable foundation
Heather Maizels speaks to Sarah Rowley about setting up a charitable foundation
Paying too high a price? The CMA’s investigations into unfair prices for hand sanitiser products
The CMA will be investigating four pharmacies and convenience stores for potentially charging excessive prices for hand sanitisers.
COVID-19 update: Companies House filings
New regulations were launched on 26 June that will temporarily extend the various filing deadlines for companies.